Shilpa Medicare zooms on getting USFDA`s final nod for Apremilast Tablets
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
https://t.me/InvestmentGuruIndiacom
Download Telegram App before Joining the Channel
Shilpa Medicare is currently trading at Rs. 256.15, up by 22.95 points or 9.84% from its previous closing of Rs. 233.20 on the BSE.
The scrip opened at Rs. 246.00 and has touched a high and low of Rs. 259.00 and Rs. 246.00 respectively. So far 79446 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 503.05 on 13-Apr-2022 and a 52 week low of Rs. 222.40 on 28-Mar-2023.
Last one week high and low of the scrip stood at Rs. 259.00 and Rs. 232.45 respectively. The current market cap of the company is Rs. 2024.22 crore.
The promoters holding in the company stood at 50.01%, while Institutions and Non-Institutions held 15.94% and 34.04% respectively.
Shilpa Medicare has received U.S Food and Drug Administration (USFDA) final approval for its ANDA, Apremilast Tablets, 10 mg, 20 mg, and 30 mg for the treatment of adult patients with active psoriatic arthritis. The product is executed from a contract manufacturing site.
Apremilast Tablets, 10 mg, 20 mg, and 30 mg is a generic equivalent of reference listed drug (RLD) OTEZLA of Celgene. The US market for Apremilast Tablets, 10 mg, 20 mg, and 30 mg is around $3.55 billion.
Shilpa Medicare produces and exports consistently high-quality Active Pharmaceutical Ingredients Fine Chemicals, intermediates, herbal products and speciality chemical products using sophisticated technology, meticulously following international specifications.
